Literature DB >> 23042324

Patent ductus arteriosus associated with pulmonary hypertension and desaturation.

Anant Khositseth1, Suthep Wanitkun.   

Abstract

We present the cases of three children with patent ductus arteriosus (PDA), pulmonary arterial hypertension (PAH), and desaturation. One of them had desaturation associated with atrial septal defect (ASD). His ASD, PAH, and desaturation improved after successful device closure of the PDA. The other two had desaturation associated with Down syndrome. One had desaturation only at room air oxygen (21% oxygen) but well saturated with 100% oxygen, subsequently underwent successful device closure of the PDA. The other had experienced desaturation at a younger age but spontaneously recovered when he was older, following attempted device closure of the PDA, with late embolization of the device.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23042324     DOI: 10.5603/cj.2012.0101

Source DB:  PubMed          Journal:  Cardiol J        ISSN: 1898-018X            Impact factor:   2.737


  4 in total

1.  Safety and Outcomes of Transcatheter Closure of Patent Ductus Arteriosus in Children With Pulmonary Artery Hypertension.

Authors:  Arash Salavitabar; Usha S Krishnan; Mariel E Turner; Julie A Vincent; Alejandro J Torres; Matthew A Crystal
Journal:  Tex Heart Inst J       Date:  2020-08-01

2.  A rare presentation of patent ductus arteriosus in an adult patient with normal pulmonary hypertension and limb edema.

Authors:  Bahram Pishgoo; Amin Saburi; Arezoo Khosravi
Journal:  ARYA Atheroscler       Date:  2014-09

3.  A novel method of creation of a fenestration in nitinol occluder devices used in closure of hypertensive patent arterial ducts.

Authors:  Anil Kumar Singhi; Kothandam Sivakumar
Journal:  Ann Pediatr Cardiol       Date:  2016 Jan-Apr

4.  A Retrospective Study of 1,526 Cases of Transcatheter Occlusion of Patent Ductus Arteriosus.

Authors:  Mei Jin; Yong-Mei Liang; Xiao-Fang Wang; Bao-Jing Guo; Ke Zheng; Yan Gu; Zhen-Yu Lyu
Journal:  Chin Med J (Engl)       Date:  2015-09-05       Impact factor: 2.628

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.